Trial Profile
Phase II Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jan 2024 Status changed from discontinued to completed.
- 06 Jun 2023 Status changed to discontinued, as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Results (Between November 2017 and April 2021) assessing the safety of consolidation pembrolizumab after proton reirradiation in patients with non-small cell lung cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.